MedTrace Logo

Control-IQ Observational (CLIO) Post-Approval Study

NCT04503174 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3157

Last updated 2023-12-08

Study results available
· View outcomes & findings →

Summary

Post-approval 522 study designed to collect primarily safety data on the US FDA-cleared product, t:slim X2 insulin pump with Control-IQ technology (Control-IQ system).

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DEVICE

t:slim X2 pump with Control-IQ technology

Real-world use

Sponsors & Collaborators

Principal Investigators

  • Jordan Pinsker, MD · Tandem Diabetes Care, Inc.

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-04
Primary Completion
2023-06-02
Completion
2023-06-26
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04503174 on ClinicalTrials.gov